All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

glycine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1319	56-40-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: glycine 2-aminoacetic acid aminoacetic acid	A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Molecular weight: 75.07 Formula: C2H5NO2 CLOGP: -3.21 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 63.32 ALOGS: 0.87 ROTB: 1

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 25, 1976	FDA	HOSPIRA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal growth restriction	78.71	56.72	15	237	7538	63481232

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vasoplegia syndrome	40.38	38.83	8	353	1848	34954722

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Compartment syndrome	42.22	38.09	9	474	5073	79738832
Vasoplegia syndrome	39.26	38.09	8	475	3622	79740283

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B05CX03	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS IRRIGATING SOLUTIONS Other irrigating solutions
MeSH PA	D018684	Glycine Agents
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:25512	neurotransmitters
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:62868	hepatoprotective agents
CHEBI has role	CHEBI:64570	serine hydroxymethyltransferase inhibitors
CHEBI has role	CHEBI:64571	NMDAR agonists
CHEBI has role	CHEBI:78675	fundamental metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Rhinitis	indication	70076002	DOID:4483
Common cold	indication	82272006	DOID:10459
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Constipation	contraindication	14760008	DOID:2089
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Osteolysis	contraindication	203522001
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160

🐶 Veterinary Drug Use

Species	Use	Relation
Cattle	Dehydration associated with diarrhea	Indication
Cattle	Early treatment of scouring	Indication
Cattle	Treatment following intravenous fluid therapy	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Re-Sorb, Vytrate	Zoetis Inc.	6

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.21	acidic
pKa2	9.94	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium- and chloride-dependent glycine transporter 1	Transporter	P48067	SC6A9_HUMAN		IC50	4.50		CHEMBL
Olfactory receptor 51E2	GPCR	Q9H255	O51E2_HUMAN		EC50	7.24		CHEMBL
Glutamate receptor ionotropic, NMDA 1	Ion channel		NMDZ1_RAT		IC50	6.60		CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT		Ki	6.77		CHEMBL

External reference:

ID	Source
TE7660XO1C	UNII
4017980	VUID
N0000146327	NUI
D00011	KEGG_DRUG
4017980	VANDF
C0017890	UMLSCUI
CHEBI:15428	CHEBI
GLY	PDB_CHEM_ID
CHEMBL773	ChEMBL_ID
750	PUBCHEM_CID
DB00145	DRUGBANK_ID
D005998	MESH_DESCRIPTOR_UI
630	INN_ID
727	IUPHAR_LIGAND_ID
4919	RXNORM
4793	MMSL
603	MMSL
NOCODE	MMSL
d06640	MMSL
000929	NDDF
003191	NDDF
15331006	SNOMEDCT_US
346464005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ProcalAmine	HUMAN PRESCRIPTION DRUG LABEL	22	0264-1915	INJECTION	0.42 g	INTRAVENOUS	NDA	24 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.36 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.36 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.36 g	INTRAVENOUS	NDA	23 sections
Glycine	HUMAN PRESCRIPTION DRUG LABEL	1	0264-2302	IRRIGANT	1.50 g	IRRIGATION	NDA	13 sections
Glycine	HUMAN PRESCRIPTION DRUG LABEL	1	0264-2302	IRRIGANT	1.50 g	IRRIGATION	NDA	13 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	1.04 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	1.04 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	1.04 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	1.04 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	1.04 g	INTRAVENOUS	ANDA	20 sections
Glycine	HUMAN PRESCRIPTION DRUG LABEL	1	0264-7390	IRRIGANT	1.50 g	IRRIGATION	NDA	13 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9010	INJECTION, SOLUTION	1.40 g	INTRAVENOUS	NDA	24 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9011	INJECTION, SOLUTION	1.40 g	INTRAVENOUS	NDA	24 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	0.36 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.22 g	INTRAVENOUS	NDA	23 sections
HepatAmine	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9371	INJECTION, SOLUTION	0.90 g	INTRAVENOUS	NDA	23 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	824 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	824 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	824 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	824 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	515 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	515 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	824 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	824 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	618 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	618 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	824 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	824 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	824 mg	INTRAVENOUS	NDA	20 sections